Rochester, NY 9/2/2009 10:21:46 PM
YMI YM BioSciences Inc., EXTEND CLINICAL PROGRAM FOR NIMOTUZUMAB
YM BioSciences Inc.
YM BioSciences Inc RECEIVES CLEARANCE FORM US Department of the Treasury’s Office of Foreign Assets Control (OFAC) to continue their research on the NIMOTUZUMAB, to further help patients with solid tumors in the US. The program will give way to develop the drug for other more useful use.
"This license from OFAC to develop nimotuzumab in any cancer indication is a major step forward in our US development program and will allow us to immediately discuss our IND submissions with the FDA to include US patients in our randomized, double-blinded lung cancer and brain metastases trials," said David Allan, Chairman and CEO of YM BioSciences. "
StockEinstein.com offers free trading alerts on stocks about to run. To sign up for our free alert service please click here www.stockeinstein.com or scroll to bottom of this page to sign up.Last Trade: 1.49
Trade Time: 10:42am ET
Change: Down 0.07 (4.49%)
Prev Close: 1.56
Open: 1.53
Day's Range: 1.41 - 1.56
52wk Range: 0.20 - 2.24
Volume: 264,415
Avg Vol (3m): 591,183
Market Cap: 83.19M
About YMI YM BioSciences Inc.
YM BioSciences Inc. is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development. The Company is currently developing two late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM), and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.
About StockEinstein
StockEinstein.com uses proprietary technologies coupled with years of experience to uncover stocks we feel have the greatest potential for breakout performance. We utilize not only software, but time tested criteria to uncover these potential winners. When these benchmarks are reached or exceeded, our subscribers are immediately notified.
This service is free and available only to subscribers. Scroll down this page or visit our site to join our free newsletter and begin receiving daily stock alerts.
Disclaimer: Full disclaimer at http://StockEinstein.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
